ReviewFundamental research2026
Smart contact lenses unlocking non-invasive eye treatment.
Review in Fundamental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The eye, serving as the primary gateway for visual information processing, is the indispensable channel through which humans perceive and interact with the external world. Structurally, it comprises an anterior segment, handling light entry and refraction, and a posterior segment, which absorbs light and transmits visual signals to the brain. Within advanced ocular healthcare, smart contact lenses (SCLs) emerged as a groundbreaking wearable technology with immense potential to revolutionize the management of diverse ocular conditions. Their inherent advantage of non-invasive and intimate corneal adherence circumvents numerous limitations of traditional therapeutic modalities. By integrating cutting-edge bio-functional components with sophisticated physical field-based therapeutic modules, therapeutic SCLs offer transformative treatment solutions to persistent challenges in conventional ocular pharmacotherapy. These lenses are poised to deliver non-invasive therapeutic interventions for a broad spectrum of ocular pathologies, spanning both anterior and posterior segments. Crucially, therapeutic SCLs effectively mitigate the risks of infection, inflammation, and other postoperative complications associated with invasive surgical procedures. Furthermore, by intelligently modulating the complex "eye-brain" pathway, SCLs introduce a paradigm-shifting strategy for managing neurovisual impairments, thereby unlocking promising avenues for restoring visual function and addressing previously intractable conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.